Small-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers
- 1State Key Laboratory of Discovery and Utilization of Functiona Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
- 2School of Biological and Environmental Engineering, Guiyang University, Guiyang 550005, China
- 3College of Food and Pharmaceutical Engineering, Guizhou Institute of Technology, Guiyang 550025, China
Abstract
Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.
Related
- Association analysis of IL-6 polymorphisms and relevant biomarkers in patients with renal failure
- Atorvastatin improves hyperlipidemia-induced erectile dysfunction via PKA-associated eNOS phosphorylation at the Ser633 site
- Causal effects between gut microbiology and hyperlipidemia : A 2-sample Mendelian randomization study
- Association of Arm Pain, Neck Pain, and Numbness Improvement with Patient Satisfaction During Pharmacological Treatment for Cervical Spine Disorders: A Prospective Multicenter Cohort Study
- A Retrospective Analysis of the Association Between Prediabetes and Biomarkers of Intestinal Permeability in Patients with Prediabetes from Durban, South Africa.
BibTeX
@article{ye2026smallleaved,
title = {{Small-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers}},
author = {Ting Ye and Jia-Hui Li and Qin-Qin Xiong and Ming-Juan Chen and Sha Cheng and Li-Rong Huang and Heng Luo},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18203345},
url = {https://www.mdpi.com/2072-6643/18/20/3345},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Small-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers
AU - Ting Ye
AU - Jia-Hui Li
AU - Qin-Qin Xiong
AU - Ming-Juan Chen
AU - Sha Cheng
AU - Li-Rong Huang
AU - Heng Luo
PY - 2026
DA - 2026/10/01
JO - Nutrients
DO - 10.3390/nu18203345
UR - https://www.mdpi.com/2072-6643/18/20/3345
AB - Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.
SN - 2072-6643
ER -